152 related articles for article (PubMed ID: 29248179)
1. Association of time-to-surgery with outcomes in clinical stage I-II pancreatic adenocarcinoma treated with upfront surgery.
Swords DS; Zhang C; Presson AP; Firpo MA; Mulvihill SJ; Scaife CL
Surgery; 2018 Apr; 163(4):753-760. PubMed ID: 29248179
[TBL] [Abstract][Full Text] [Related]
2. Facility volume-survival relationship in patients with early-stage pancreatic adenocarcinoma treated with neoadjuvant chemotherapy followed by pancreatoduodenectomy.
Hue JJ; Sugumar K; Markt SC; Hardacre JM; Ammori JB; Rothermel LD; Winter JM; Ocuin LM
Surgery; 2021 Jul; 170(1):207-214. PubMed ID: 33454134
[TBL] [Abstract][Full Text] [Related]
3. Overall survival is increased among stage III pancreatic adenocarcinoma patients receiving neoadjuvant chemotherapy compared to surgery first and adjuvant chemotherapy: An intention to treat analysis of the National Cancer Database.
Shubert CR; Bergquist JR; Groeschl RT; Habermann EB; Wilson PM; Truty MJ; Smoot RL; Kendrick ML; Nagorney DM; Farnell MB
Surgery; 2016 Oct; 160(4):1080-1096. PubMed ID: 27522556
[TBL] [Abstract][Full Text] [Related]
4. Pathologic upstaging in resected pancreatic adenocarcinoma: Risk factors and impact on survival.
Olecki EJ; Stahl KA; Torres MB; Peng JS; Shen C; Dixon MEB; Gusani NJ
J Surg Oncol; 2021 Jul; 124(1):79-87. PubMed ID: 33836095
[TBL] [Abstract][Full Text] [Related]
5. Hospital-level Variation in Utilization of Surgery for Clinical Stage I-II Pancreatic Adenocarcinoma.
Swords DS; Mulvihill SJ; Skarda DE; Finlayson SRG; Stoddard GJ; Ott MJ; Firpo MA; Scaife CL
Ann Surg; 2019 Jan; 269(1):133-142. PubMed ID: 28700442
[TBL] [Abstract][Full Text] [Related]
6. Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal adenocarcinoma.
Glazer ES; Rashid OM; Pimiento JM; Hodul PJ; Malafa MP
Surgery; 2016 Nov; 160(5):1288-1293. PubMed ID: 27450715
[TBL] [Abstract][Full Text] [Related]
7. Improved long-term outcomes after resection of pancreatic adenocarcinoma: a comparison between two time periods.
Serrano PE; Cleary SP; Dhani N; Kim PT; Greig PD; Leung K; Moulton CA; Gallinger S; Wei AC
Ann Surg Oncol; 2015 Apr; 22(4):1160-7. PubMed ID: 25348784
[TBL] [Abstract][Full Text] [Related]
8. Value of lymph node positivity in treatment planning for early stage pancreatic cancer.
Tran Cao HS; Zhang Q; Sada YH; Silberfein EJ; Hsu C; Van Buren G; Chai C; Katz MHG; Fisher WE; Massarweh NN
Surgery; 2017 Sep; 162(3):557-567. PubMed ID: 28666686
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant Therapy Followed by Resection Versus Upfront Resection for Resectable Pancreatic Cancer: A Propensity Score Matched Analysis.
Mokdad AA; Minter RM; Zhu H; Augustine MM; Porembka MR; Wang SC; Yopp AC; Mansour JC; Choti MA; Polanco PM
J Clin Oncol; 2017 Feb; 35(5):515-522. PubMed ID: 27621388
[TBL] [Abstract][Full Text] [Related]
10. External radiation is associated with limited improvement in overall survival in resected margin-negative stage IIB pancreatic adenocarcinoma.
Kantor O; Talamonti MS; Lutfi W; Wang CH; Winchester DJ; Marsh R; Prinz RA; Baker MS
Surgery; 2016 Dec; 160(6):1466-1476. PubMed ID: 27614417
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant therapy versus upfront surgery for resected pancreatic adenocarcinoma: A nationwide propensity score matched analysis.
de Geus SW; Eskander MF; Bliss LA; Kasumova GG; Ng SC; Callery MP; Tseng JF
Surgery; 2017 Mar; 161(3):592-601. PubMed ID: 28341441
[TBL] [Abstract][Full Text] [Related]
12. Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival.
Rose JB; Rocha FG; Alseidi A; Biehl T; Moonka R; Ryan JA; Lin B; Picozzi V; Helton S
Ann Surg Oncol; 2014 May; 21(5):1530-7. PubMed ID: 24473642
[TBL] [Abstract][Full Text] [Related]
13. Total pancreatectomy for pancreatic ductal adenocarcinoma: review of the National Cancer Data Base.
Johnston WC; Hoen HM; Cassera MA; Newell PH; Hammill CW; Hansen PD; Wolf RF
HPB (Oxford); 2016 Jan; 18(1):21-8. PubMed ID: 26776847
[TBL] [Abstract][Full Text] [Related]
14. A comparative analysis of survival outcomes between pancreatectomy and chemotherapy for elderly patients with adenocarcinoma of the pancreas.
Marmor S; Burke EE; Virnig BA; Jensen EH; Tuttle TM
Cancer; 2016 Nov; 122(21):3378-3385. PubMed ID: 27419382
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors in resected pancreatic adenocarcinoma: analysis of actual 5-year survivors.
Cleary SP; Gryfe R; Guindi M; Greig P; Smith L; Mackenzie R; Strasberg S; Hanna S; Taylor B; Langer B; Gallinger S
J Am Coll Surg; 2004 May; 198(5):722-31. PubMed ID: 15110805
[TBL] [Abstract][Full Text] [Related]
16. Perioperative chemotherapy is associated with a survival advantage in early stage adenocarcinoma of the pancreatic head.
Lutfi W; Talamonti MS; Kantor O; Wang CH; Liederbach E; Stocker SJ; Bentrem DJ; Roggin KK; Winchester DJ; Marsh R; Prinz RA; Baker MS
Surgery; 2016 Sep; 160(3):714-24. PubMed ID: 27422328
[TBL] [Abstract][Full Text] [Related]
17. Survival benefit of neoadjuvant therapy in patients with non-metastatic pancreatic ductal adenocarcinoma: A propensity matching and intention-to-treat analysis.
Sugimoto M; Takahashi N; Farnell MB; Smyrk TC; Truty MJ; Nagorney DM; Smoot RL; Chari ST; Carter RE; Kendrick ML
J Surg Oncol; 2019 Nov; 120(6):976-984. PubMed ID: 31452208
[TBL] [Abstract][Full Text] [Related]
18. Multimodality therapy for pancreatic cancer in the U.S. : utilization, outcomes, and the effect of hospital volume.
Bilimoria KY; Bentrem DJ; Ko CY; Tomlinson JS; Stewart AK; Winchester DP; Talamonti MS
Cancer; 2007 Sep; 110(6):1227-34. PubMed ID: 17654662
[TBL] [Abstract][Full Text] [Related]
19. Clinical and pathological features of five-year survivors after pancreatectomy for pancreatic adenocarcinoma.
Kimura K; Amano R; Nakata B; Yamazoe S; Hirata K; Murata A; Miura K; Nishio K; Hirakawa T; Ohira M; Hirakawa K
World J Surg Oncol; 2014 Nov; 12():360. PubMed ID: 25429841
[TBL] [Abstract][Full Text] [Related]
20. The efficacy of adjuvant therapy for pancreatic invasive intraductal papillary mucinous neoplasm (IPMN).
McMillan MT; Lewis RS; Drebin JA; Teitelbaum UR; Lee MK; Roses RE; Fraker DL; Vollmer CM
Cancer; 2016 Feb; 122(4):521-33. PubMed ID: 26587698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
